|
Experimental once-weekly diabetes drug dulaglutide proved superior in late-stage clinical trials to three other widely used medicines that are dosed more frequently according to Eli Lilly. Dulaglutide lowered HbA1c levels more than twice-daily injections of exenatide given for six months, oral metformin taken for 26 weeks and once-daily oral sitagliptin taken for one year. Lilly expects to submit to the FDA in 2013. Eli Lilly Press Release, Oct. 25, 2012 |
